Recilisib sodium (formerly known as ON 01210.Na; ON-01210; ON01210; EX-RAD), the soiumd salt of recilisib, is a radioprotectant that is being studies in phase 1 clinical trials by Onconova Therapeutics for the treatment of acute radiation syndrome. It is able to mitigate radiation damage through activation of the AKT pathway. Recilisib modifies cell cycle distribution patterns in cancer cells subjected to radiation therapy, and it has been identified as a potential candidate for radiation protection studies. It appears that Recilisib radioprotective mechanisms involve prevention of p53-dependent and independent radiation-induced apoptosis.

纯度：≥98%

CAS：922139-31-9